The viral relapses seen in genotypes 1 are interesting wrt virus biology. My take is that there is a pool of genotype 1 virus not reached by the drugs and not measured by current testing protocols; once the drug is removed that pool reinfects the liver cells and the disease rebounds. Does anyone else have a different interpretation? If that's true, the question then becomes can you address that pool by lengthening time of treatment or do you need a different drug? So are the viriads in that unreached pool actively replicating or is it a quiescent reservoir that dies out as the virus' natural lifecycle ends?
Market Data 
Markets 
AI
